Immunocore Holdings plc (IMCR) stock
IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3012% below fair value
$28.88−1.06 (-3.54%)
Close on Nov 16, 2026Market cap $1.49BP/E –Yield 0.00%
Immunocore profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Immunocore's profit margin for the twelve months ending Jun 30, 2026 was -4.2%. For fiscal 2025 it was -8.9%, against -16.5% the year before. The highest annual figure on record is -8.9% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -8.9% | +7.6 |
| FY2024 | Dec 31, 2024 | -16.5% | +5.7 |
| FY2023 | Dec 31, 2023 | -22.2% | +8.0 |
| FY2022 | Dec 31, 2022 | -30.1% | +463.3 |
| FY2021 | Dec 31, 2021 | -493.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -0.7% | +9.8 |
| Q1 FY2026 | Mar 31, 2026 | 12.2% | +6.8 |
| Q4 FY2025 | Dec 31, 2025 | -28.8% | −0.5 |
| Q3 FY2025 | Sep 30, 2025 | -0.2% | −11.1 |
| Q2 FY2025 | Jun 30, 2025 | -10.5% | +4.9 |
| Q1 FY2025 | Mar 31, 2025 | 5.4% | +40.0 |
| Q4 FY2024 | Dec 31, 2024 | -28.3% | −0.2 |
| Q3 FY2024 | Sep 30, 2024 | 10.9% | +9.5 |
| Q2 FY2024 | Jun 30, 2024 | -15.4% | +13.1 |
| Q1 FY2024 | Mar 31, 2024 | -34.7% | +0.9 |
| Q4 FY2023 | Dec 31, 2023 | -28.1% | – |
| Q3 FY2023 | Sep 30, 2023 | 1.4% | – |
| Q2 FY2023 | Jun 30, 2023 | -28.5% | – |
| Q1 FY2023 | Mar 31, 2023 | -35.6% | – |
See a number that looks wrong?